iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Pricing of Drugs and Formulary Placement: Making Sense of Hepatitis C Treatment Camilla S. Graham, MD, MPH
 
 
  Download the PDF here
 
Co-Director, Viral Hepatitis Center, Division of Infectious Disease Beth Israel Deaconess Medical Center and Harvard Medical School
Boston, Massachusetts
Tuesday, March 31, 2015
 
GOLD SUPPORTERS
Bristol-Myers Squibb
AbbVie
Gilead Sciences, Inc
SILVER SUPPORTER
Merck & Co, Inc
 
https://www.iasusa.org/content/pricing-of-drugs-and-formulary-placement-webinar-2015
 
https://iasusa.adobeconnect.com/_a1090822362/p2h0yk85lmq/?launcher=false&fcsContent=true&pbMode=normal (ok to skip the first 5-7 minutes of the presentation)
 

HCV1.gif

Confusion and doubt: Who should we be treating?
Fear of testing: Why make people anxious and not be able to treat them?
Public health programs stymied because why find people and then not be able to treat them?
Deliberate rationing
Vulnerable patient population already stigmatized, now experiencing overt discrimination, in effect telling patients they aren't worthy of being treated.
 
Landscape is complex and changing quickly.
 
How did we get ourselves into this mess?
 

HCV1.gif

HCV2.gif

HCV3.gif

HCV4.gif

HCV5.gif

HCV6.gif

HCV7.gif

HCV8.gif

HCV9.gif

HCV10.gif

HCV11.gif

HCV12.gif

HCV13.gif

HCV14.gif

HCV15.gif

HCV16.gif

HCV17.gif

HCV18.gif

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org